Glecirasib: KRAS G12C-mutated lung cancerSeek tumour shrinkage after lung cancer progression,
with a daily oral medicine for a specific mutation.
Eligible adults with advanced KRAS G12C-mutated non-small cell lung cancer needing a change after systemic treatment may use glecirasib to seek tumour shrinkage. The Chinese phase IIb single-arm study reported a confirmed response rate of 47.9%, not an individual's success rate. Daily oral treatment still requires scheduled liver function and blood count monitoring.
Free initial service consultation · Understand your options and budget before you travel
- Confirmed objective response rate
- 47.9%, 56/117 evaluable patients
- Grade 3–4 treatment-related adverse events
- 38.7%, 46/119 patients
Based on the original paper with data cut-off 2024-03-28; a single-arm study, and response does not mean cure. View the evidence
Limited to specific previously treated adult KRAS G12C lung cancer. The price comes from a 2026 Chongqing report that does not state tablets per box, so it is not a standard 30-day quote. Foreign patients pay in full without insurance or free drugs. View sources
After progression, turn a genetic target into a medication plan
Glecirasib is a domestically developed oral medicine commercially available in China for specific previously treated KRAS G12C lung cancer. Review genetic results, previous responses and safety with a specialist when discussing the next prescription and reassessment.
Match the medicine to the exact variant
Confirm G12C rather than another KRAS variant. Previous use of a drug in the same class requires a separate resistance assessment; a switch is not guaranteed to work.
Connect daily medication with long-term monitoring
Plan ongoing prescriptions and imaging assessment around liver function, blood counts and all concurrent medicines. Convenience does not remove the need for monitoring.
Assess the monthly burden and plan continued treatment
Use the price per box and monthly consumption reported publicly in Chongqing in 2026 as budget references. Foreign patients are fully self-funded without Chinese health insurance or free drugs; actual pack size, prescription and costs still need confirmation.
- Public Chongqing report, 2026
- RMB 4,000 per box; the reported patient used 3 boxes monthly
- Estimate based on reported consumption
- Approximately RMB 12,000 per month in drug costs; verify pack size and prescription
- Baseline examinations
- Pathology, KRAS testing, imaging, blood counts and biochemistry require pricing
- Ongoing follow-up
- Consultations, imaging, liver function and management of side effects are additional
The public report does not specify tablets per box and is not treated as a standard 30-day quote. Treatment duration varies; international consultations and travel are additional.
Finding treatment that fits you
starts with the reports you already have.
Clarifying your disease type and previous treatment helps establish whether this option could form part of a plan for you.
- Disease and ageAdults with advanced non-small cell lung cancer and confirmed KRAS G12C.
- Previous treatmentAt least one previous systemic treatment; this page is not a routine first-line recommendation.
- Baseline safetyTell the doctor fully about recent immunotherapy, liver injury and other medicines.
Consider the chance of tumour shrinkage alongside drug risks
The original phase IIb paper enrolled 119 patients and observed antitumour activity. Confirmed response does not mean cure. Ongoing treatment also requires assessment of tolerance through liver function, blood counts and respiratory symptoms.
- Design
- Multicentre, open-label, single-arm; study dose 800mg once daily
- Primary endpoint
- Independently reviewed confirmed tumour response
- Key monitoring needs
- Raised liver enzymes and bilirubin, and anaemia; watch for new or worsening respiratory symptoms
Separate single-arm trials cannot directly establish superiority to sotorasib or adagrasib. Conditional approval still requires confirmatory studies.
You do not need to book flights first.
Clarify treatment and costs before you travel.
Tell us your diagnosis, previous treatments and main concerns. We help you communicate about Shanghai consultation requirements, budgets and travel arrangements.
- Provide pathology, staging and recent original CT images to identify lesions requiring attention
- Bring the complete KRAS G12C report and sample information to confirm the variant
- Organise dates and responses for previous chemotherapy, immunotherapy or targeted medicines to assess the basis for switching
- Provide recent liver tests, blood counts and a list of prescription medicines and supplements to plan safety checks
Start the first conversation with the records you already have.
You do not need to arrange new tests yourself for an initial consultation.
Get answers to the questions that matter to you
before you travel.
Costs, potential benefit and further treatment deserve specific answers before departure.
Can I start treatment if my report says KRAS-positive?
The variant must specifically be G12C, with adult advanced non-small cell lung cancer after at least one systemic treatment. Other variants do not qualify, and these findings do not support routine first-line use.
Will glecirasib work after another G12C medicine?
There is no guarantee. Cross-resistance may limit benefit; previous response and the cause of progression must be considered. Response rates from different single-arm studies cannot directly rank drugs.
Do I still need to budget for medication after the tumour shrinks?
Treatment usually continues until progression or intolerance, with scheduled reassessment. Contact the team promptly for jaundice, marked fatigue or worsening breathlessness.
Plan daily treatment together with prescriptions, reassessment and your budget.
Starting with your condition and budget, we help communicate about consultations and treatment arrangements in Shanghai.
The initial service consultation is free; the treating doctor assesses your specific medical plan.
Sources and image credits
Information is compiled from public approval documents, studies and prices and does not replace an individual medical assessment. Research and cost figures each have a defined scope; published prices are not personal international patient quotes. Costs are discussed on a self-funded basis without Chinese health insurance or free-drug assistance.
- Jacobio official announcement: glecirasib marketing approval in China · 2025-05; verified 2026-10-03
- Company submission published by the National Healthcare Security Administration: glecirasib indications, dosing and risks · 2025-07-18
- Shi et al.: original phase IIb glecirasib paper in KRAS G12C lung cancer · 2025-01-06
- Chongqing Municipal Government: reported glecirasib box price and monthly consumption · 2026-01-11
- Chinese Academy of Medical Sciences and Peking Union Medical College: official Shi Yuankai profile · Verified 2026-10-03